A randomized, open label, phase II trial of Anti-PD1, dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510268-11-00

Acronym

GEICO78-C (ATOMICC)

Enrollment

132

Registered

2024-03-08

Start date

2019-06-11

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer

Brief summary

Progression Free Survival (PFS)

Detailed description

Overall survival (OS), Health-related quality of life (HRQOL) measure by the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) and EQ-5D-5L., Fatigue measure by the PROMIS-Cancer-Fatigue Short Form 4a, Pain measure by a single item of the Brief Pain Inventory (BPI).

Interventions

DRUGJEMPERLI 500 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS)	—

Secondary

Measure	Time frame
Overall survival (OS), Health-related quality of life (HRQOL) measure by the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) and EQ-5D-5L., Fatigue measure by the PROMIS-Cancer-Fatigue Short Form 4a, Pain measure by a single item of the Brief Pain Inventory (BPI).	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026